NCT04392505 - Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

May 11, 2020

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2033

Conditions

CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer Stage IIINSCLCNSCLC, Stage III

Interventions

DRUG

Durvalumab Injection

Included patients will receive durvalumab (fixed dose, 1500mg Q4W) until progressive disease and no clinical benefit, intolerable toxicity or patient's wish, for a maximum duration of 12 months. Treatment with durvalumab should start \<5 weeks after last radiotherapy dosing.

Trial Locations (10)

33520

Tampere University Hospital, Tampere

Unknown

North Estonia Medical Centre, Tallinn

Oulu University Hospital, Oulu

Turku University Hospital, Turku

National Cancer Institute, Vilnius

Haukeland universitetssykehus, Bergen

Oslo University Hospital, Oslo

Stavanger University Hospital, Stavanger

Universitetssykehuset i Nord-Norge, Tromsø

St. Olavs Hospital, Trondheim